Cargando…

The role of oncogenic MUC1-C in brachyury-induced immunotherapy resistance

Detalles Bibliográficos
Autores principales:	David, Justin, Hamilton, Duane, Schlom, Jeffrey, Palena, Claudia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288654/ http://dx.doi.org/10.1186/2051-1426-2-S3-P48

Ejemplares similares

Upregulation of oncogenic MUC1 by the EMT transcription factor brachyury mediates immunotherapy-resistance in tumor cells
por: David, Justin M, et al.
Publicado: (2015)

Brachyury, a driver of tumor invasiveness and resistance to multiple therapies, is a novel immunotherapy target
por: Palena, Claudia, et al.
Publicado: (2013)

MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition
por: David, Justin M., et al.
Publicado: (2016)

High levels of expression of the transcription factor Brachyury induce resistance of human carcinoma cells to immune-mediated attack
por: Hamilton, Duane H, et al.
Publicado: (2013)

Aberrant expression of the embryonic transcription factor brachyury in human tumors detected with a novel rabbit monoclonal antibody
por: Hamilton, Duane H., et al.
Publicado: (2014)

Generation of human T cells directed against an agonist epitope of Brachyury, a transcription factor involved in human tumor cell epithelial to mesenchymal transition (EMT)
por: Boyerinas, Benjamin, et al.
Publicado: (2013)

Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses
por: Heery, Christopher R, et al.
Publicado: (2015)

Identification of tumor associated immune responses against brachyury, a transcription factor and driver of EMT, in chordoma patients receiving a yeast-brachyury vaccine (gi-6301)
por: Donahue, Renee N, et al.
Publicado: (2014)

Loss of the Cyclin-Dependent Kinase Inhibitor 1 in the Context of Brachyury-Mediated Phenotypic Plasticity Drives Tumor Resistance to Immune Attack
por: Hamilton, Duane H., et al.
Publicado: (2018)

Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine
por: Hamilton, Duane H., et al.
Publicado: (2013)

Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)
por: Bilusic, Marijo, et al.
Publicado: (2021)

Identification and characterization of agonist epitopes of the MUC1-C oncoprotein
por: Jochems, Caroline, et al.
Publicado: (2013)

A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer
por: Gatti‐Mays, Margaret E., et al.
Publicado: (2019)

Interleukin-8 drives epithelial-mesenchymal transition of human carcinomas
por: Fernando, Romaine I, et al.
Publicado: (2013)

Development of breast cancer immunotherapy using MUC1 retargeted T lymphocytes
por: Wilkie, S, et al.
Publicado: (2006)

Systemic immunotherapy of superficial mouse bladder cancer with Avelumab (MSB0010718C), an anti-PD-L1 immune checkpoint inhibitor
por: Vandeveer, Amanda, et al.
Publicado: (2015)

The embryonic transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to conventional antitumor therapies
por: Huang, B, et al.
Publicado: (2013)

Vaccine Increases the Diversity and Activation of Intratumoral T Cells in the Context of Combination Immunotherapy
por: Horn, Lucas A., et al.
Publicado: (2021)

Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis
por: Dahut, Madeline, et al.
Publicado: (2023)

Vaccines against Human Carcinomas: Strategies to Improve Antitumor Immune Responses
por: Palena, Claudia, et al.
Publicado: (2010)

Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer
por: DeMaria, Peter J, et al.
Publicado: (2021)

The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance
por: David, Justin M., et al.
Publicado: (2016)

The generation and analysis of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic
por: Tsang, Kwong Y, et al.
Publicado: (2015)

Role of CCND1 and C-MYC oncogenes in metastatic breast cancer patients treated by herceptin
por: Trojanec, R, et al.
Publicado: (2011)

Development of breast cancer immunotherapy using MUC1-retargeted T lymphocytes
por: Wilkie, S, et al.
Publicado: (2008)

A165 FCGBP IN THE COLON IS SPATIALLY DEPENDENT ON MUC2 EXPRESSION AND IS DEGRADED IN DEXTRAN SULFATE SODIUM-INDUCED COLITIS
por: Kim, A, et al.
Publicado: (2023)

Development of anti-MUC1 DNA aptamers for the imaging and radiotherapy of breast cancer
por: Da Pieve, C, et al.
Publicado: (2006)

Development of anti-MUC1 DNA aptamers for the imaging and radiotherapy of breast cancer
por: Da Pieve, C, et al.
Publicado: (2008)

The Roles of Embryonic Transcription Factor BRACHYURY in Tumorigenesis and Progression
por: Chen, Ming, et al.
Publicado: (2020)

Targeting cytomegalovirus (CMV) antigens for GBM immunotherapy
por: Nair, Smita K, et al.
Publicado: (2013)

Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death
por: Smith, Andressa A, et al.
Publicado: (2013)

Preclinical evaluation of MVA-MUC1-IL2 in combination with chemotherapy in murine models
por: De Meyer, Micaël, et al.
Publicado: (2013)

Effects of tyrosine kinase inhibitors alone or in combination with vaccine on tumor-infiltrating myeloid cells
por: Donahue, Renee N, et al.
Publicado: (2013)

From Notochord Formation to Hereditary Chordoma: The Many Roles of Brachyury
por: Nibu, Yutaka, et al.
Publicado: (2013)

Disorders of the cMyb proto-oncogene expression and its significance in the course of ATL development
por: Nakano, Kazumi, et al.
Publicado: (2014)

Tumor hypoxia drives immune suppression and immunotherapy resistance
por: Ai, Midan, et al.
Publicado: (2015)

Phase 1 dose escalation of ONT-10, a therapeutic MUC1 vaccine, in patients with advanced cancer
por: Nemunaitis, John, et al.
Publicado: (2013)

The oncogenic role of MUC12 in RCC progression depends on c‐Jun/TGF‐β signalling
por: Gao, Sheng‐Lin, et al.
Publicado: (2020)

An Interleukin-15 Superagonist Enables Antitumor Efficacy of Natural Killer Cells Against All Molecular Variants of SCLC
por: Fousek, Kristen, et al.
Publicado: (2023)

Tumor associated MUC1 carried by microvesicles is cross-processed by dendritic cells generating CD8+ T cell response
por: Zizzari, Ilaria G, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_h674kvnfitaemhbs4pqqq9ngri